Analytes | Baricitinib 4 mg vs placebo plus SOC at week 12 | ||
FC | P value | Adjusted p value | |
CCL19 | −1.8 | <0.001 | <0.001 |
IL-6 | −1.5 | <0.001 | 0.002 |
TNFRSF9 | −1.4 | <0.001 | <0.001 |
CXCL10 | −1.3 | 0.003 | 0.011 |
IL-12β | −1.3 | <0.001 | <0.001 |
TNF-α | −1.2 | <0.001 | <0.001 |
PD-L1 | −1.2 | <0.001 | <0.001 |
An adjusted p value of 0.0237 was used as the cut-off for within-protein significance (see Statistical analyses section in Methods).
CCL19, C-C motif chemokine ligand 19; CXCL10, C-X-C motif chemokine ligand 10; FC, fold change; IL-6, interleukin-6; IL-12β, interleukin-12 beta chain; PD-L1, PDCD1 ligand 1; SLE, systemic lupus erythematosus; SOC, standard of care; TNFRSF9, TNF receptor superfamily member 9; TNF-α, tumour necrosis factor alpha.